The FDA has cleared NeuroSigma’s second-generation Monarch eTNS System for treatment of pediatric ADHD, the company announced in a press release.The Monarch 2.0 device is approximately one-third the size of the first-generation Monarch eTNS System and includes a high-resolution color LCD screen and optimized user interface. It is indicated as a monotherapy for patients aged 7 to 12 years
